Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forLON:BGC
795.00
+3.00 (0.38%)
Jan 28 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 788.00 - 802.00
52 week 490.20 - 835.87
Open 801.00
Vol / Avg. 444,418.00/641,291.00
Mkt cap 3,034.54M*
P/E 73.10
Div/yield     -
EPS 0.11*
Shares 381.70M
Beta     -
Inst. own     -
*GBP
Apr 1, 2015
BTG PLC Close Period Trading Statement Release (Estimated) Add to calendar
Feb 3, 2015
BTG PLC Interim Management Statement Release - 8:00am GMT - Add to calendar
Jan 14, 2015
BTG PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 14, 2015
BTG PLC at JPMorgan Healthcare Conference
Dec 4, 2014
BTG PLC Acquisition of PneumRx Call
Nov 11, 2014
Half Year 2015 BTG PLC Earnings Call
Nov 11, 2014
Half Year 2015 BTG PLC Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 20.50% 8.36%
Operating margin 21.71% 9.40%
EBITD margin - 24.30%
Return on average assets 10.63% 3.87%
Return on average equity 14.07% 5.04%
Employees 776 -
CDP Score - 55 D

Address

5 Fleet Place
LONDON, EC4M 7RD
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots and patients with varicose veins in the great saphenous vein system of the leg. Its Specialty Pharmaceutical products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. Its Licensing business area consists of licensed products and programs and generates royalties for the Company. The Company�s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd, BTG Employee Share Schemes Ltd and PneumRx Inc.

Officers and directors

Louise Makin Ph.D. Chief Executive Officer, Executive Director
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Melanie G. Lee Ph.D., CBE Part Time Chief Scientific Officer
Age: 56
Paul Mussenden Company Secretary
Garry Andrew Watts MBE Non-Executive Chairman of the Board
Age: 57
Giles F. B. Kerr Senior Independent Non-Executive Director
Ian F. R. Much Independent Non-Executive Director
W. James O'Shea Independent Non-Executive Director
Age: 63
Richard Wohanka Independent Non-Executive Director